A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI33

Trial Profile

A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI33

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker
  • Acronyms DISPERSE-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 May 2016 Results (pooled analysis of DISPERSE-2 and PLATO PK substudy, n = 6990) assessing population pharmacokinetics of ticagrelor published in the International Journal of Clinical Pharmacology and Therapeutics.
    • 02 Nov 2012 New source identified and integrated: European Clinical Trials Database record.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top